Research programme: obesity therapy - AmbrxAlternative Names: ARX-328
Latest Information Update: 09 Jan 2014
At a glance
- Originator Ambrx
- Class Adipokines
- Mechanism of Action Leptin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 09 Jan 2014 Preclinical development is ongoing in USA
- 08 Jul 2011 Preclinical trials in Obesity in USA (unspecified route)